Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label randomized study of GLM101 in adults with PMM2-CDG
2022-000565-40Phase 2Active
- Sponsor
- Glycomine
- Start
- Aug 2022
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GLM101 in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG) (2 arms), sponsored by Glycomine. Primary endpoint: Change in antithrombin III (ATIII) activity level. Started Aug 2022; status: active.
02
Drugs
GLM101
03
Conditions
phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG)
Beyond the preview
Go deeper on 2022-000565-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000565-40.